

Organisatorisches

Teilnahmegebühr

Die Veranstaltung ist kostenlos

Zertifizierung

Fortbildungspunkte sind bei der Bayerischen Landesärztekammer beantragt

Organisation

Prof. Dr. Hermann Einsele
Prof. Dr. Martin Kortüm
Dr. Leo Rasche
Brigitte Schäfer
Gabriele Nelkenstock

Anmeldung

Gabriele Nelkenstock
Telefon: 0931 / 880 79 447 · Fax: 880 79 448
E-Mail: info@gn-beratung.de

Veranstaltungsorte

Best Western Premier Hotel Rebstock
Hof Engelgarten im Kapitelsaal
Neubaustraße 7, 97070 Würzburg

Würzburg Residence Conference Center
Residenzplatz 2, 97070 Würzburg


Veranstalter

Medizinische Klinik und Poliklinik II
Oberdürrbacher Straße 6, Haus A3/A4
97080 Würzburg

Besuchen Sie unsere Homepage:
www.ukw.de/medizin2

Gestaltung:  design@ukw.de, Titelbild: Giovanni Cancemi | stock.adobe.com

Save
the
date

Uniklinikum
Würzburg 

5th Würzburg Myeloma Workshop

27. und 28. März 2020

27. März 2020 · Beginn 11.00 Uhr

Best Western Premier Hotel Rebstock
Hof Engelgarten im Kapitelsaal
Neubaustraße 7, 97070 Würzburg

28. März 2020 · Beginn 09.00 Uhr

Würzburg Residence Conference Center
Residenzplatz 2, 97070 Würzburg


Comprehensive Cancer Center
Mainfranken



Friday, March 27th

Lecture Hall, Hof Engelgarten, Hotel Rebstock, Würzburg

- ▶ **Lessons from the myeloma genome project**
Gareth Morgan, NY, USA
- ▶ **Clone wars in myeloma evolution: Darwin or Big Bang?**
Martin Kaiser, London, UK
- ▶ **The myeloma microenvironment: ignored or overrated?**
Madhav V. Dhodapkar, Atlanta, USA
- ▶ **Functional imaging in multiple myeloma**
Elena Zamagni, Bologna, IT
- ▶ **Genetics associated with High-Risk disease**
Herve Avet-Loseau, Toulouse, FR
- ▶ **Double hit myelomas**
Brian Walker, Indiana, USA
- ▶ **How I define and treat high-risk multiple myeloma**
Frits van Rhee, Little Rock, USA
- ▶ **Multiple Myelomas – introducing tumor heterogeneity in MM**
Niels Weinhold, Heidelberg, GER
- ▶ **MM Precision Medicine at the Mayo clinic – today and tomorrow**
Keith Stewart, Scottsdale, USA
- ▶ **NGS guided Targeted and immune therapies in MM- the Mount Sinai approach**
Samir Parekh, NY, USA
- ▶ **Targeting BRAF and other mutations in MM**
Marc Raab, Heidelberg, GER
- ▶ **Venetoclax: The first targeted therapy for MM?**
Cyrille Tozeau, Nantes, FR
- ▶ **Carfilzomib: Low-dose – standard dose – or high dose?**
Christoph Driessen, St. Gallen, CH

Saturday, March 28th

Würzburg Residence Conference Center

- ▶ **How do we measure MRD in MM? NGS, NGF, and Imaging?**
Joaquin Martinez Lopez, Madrid, ESP
- ▶ **Clinical case presentations on the issue MRD**
Martin Kortüm, Würzburg, GER; Leo Rasche, Würzburg, GER
- ▶ **MRD triggered treatment decisions: Today and tomorrow**
Faith Davies, NY, USA
- ▶ **Keynote Lecture: Treatment for patients who fill only slim CRAB criteria or smoldering myeloma**
Yes: Sagar Lonial, Atlanta, USA
No: Heinz Ludwig, Vienna, A
- ▶ **Keynote Lecture: BCMA CARs on the road to cure?**
Nina Shah, LA, USA
- ▶ **CARs addressing alternative targets**
Michael Hudecek, Würzburg, GER
- ▶ **MM bispecifics – The Würzburg experience**
Hermann Einsele, Würzburg, GER
- ▶ **Keynote Lecture: Antibody drug conjugates**
Suzanne Trudel, Toronto, CAN
- ▶ **Novel drugs on the horizon**
Charlotte Pawlyn, London, UK
- ▶ **Immunomodulatory drugs: CRBN and beyond**
Florian Bassermann, München, GER
- ▶ **From mice to men: What can we learn from murine MM models?**
Andreas Beilhack, Würzburg, GER
- ▶ **German speaking Myeloma Multicenter Group Current and Novel Trials of GMMG**
Hartmut Goldschmidt, Heidelberg, GER
- ▶ **Current and Novel Trials of DSMM**
Stefan Knop, Würzburg, GER